[go: up one dir, main page]

DE60035575D1 - Verwendubg von 3-hydroxy-3-methylglutaryl coenzym a reduktase inhibitoren zur herstellung eines medikaments zur behandlung der diabetischen neuropathie - Google Patents

Verwendubg von 3-hydroxy-3-methylglutaryl coenzym a reduktase inhibitoren zur herstellung eines medikaments zur behandlung der diabetischen neuropathie

Info

Publication number
DE60035575D1
DE60035575D1 DE60035575T DE60035575T DE60035575D1 DE 60035575 D1 DE60035575 D1 DE 60035575D1 DE 60035575 T DE60035575 T DE 60035575T DE 60035575 T DE60035575 T DE 60035575T DE 60035575 D1 DE60035575 D1 DE 60035575D1
Authority
DE
Germany
Prior art keywords
coenzym
methylglutaryl
medicament
hydroxy
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60035575T
Other languages
English (en)
Other versions
DE60035575T2 (de
Inventor
Norman E Cameron
Mary A Cotter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Aberdeen
AstraZeneca AB
Original Assignee
University of Aberdeen
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902591.8A external-priority patent/GB9902591D0/en
Priority claimed from GBGB9902594.2A external-priority patent/GB9902594D0/en
Application filed by University of Aberdeen, AstraZeneca AB filed Critical University of Aberdeen
Publication of DE60035575D1 publication Critical patent/DE60035575D1/de
Application granted granted Critical
Publication of DE60035575T2 publication Critical patent/DE60035575T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60035575T 1999-02-06 2000-02-01 Verwendubg von 3-hydroxy-3-methylglutaryl coenzym a reduktase inhibitoren zur herstellung eines medikaments zur behandlung der diabetischen neuropathie Expired - Lifetime DE60035575T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9902591.8A GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
GB9902591 1999-02-06
GB9902594 1999-02-06
GBGB9902594.2A GB9902594D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
PCT/GB2000/000280 WO2000045818A1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy

Publications (2)

Publication Number Publication Date
DE60035575D1 true DE60035575D1 (de) 2007-08-30
DE60035575T2 DE60035575T2 (de) 2008-04-03

Family

ID=26315085

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60035575T Expired - Lifetime DE60035575T2 (de) 1999-02-06 2000-02-01 Verwendubg von 3-hydroxy-3-methylglutaryl coenzym a reduktase inhibitoren zur herstellung eines medikaments zur behandlung der diabetischen neuropathie
DE60045168T Expired - Lifetime DE60045168D1 (de) 1999-02-06 2000-02-01 Kombinationspräparate enthaltend (E)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r,5s)-3,5-dihydroxyhept-6-enoic Säure

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60045168T Expired - Lifetime DE60045168D1 (de) 1999-02-06 2000-02-01 Kombinationspräparate enthaltend (E)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r,5s)-3,5-dihydroxyhept-6-enoic Säure

Country Status (34)

Country Link
US (4) US6894058B1 (de)
EP (2) EP1897546B1 (de)
JP (3) JP2002536332A (de)
KR (1) KR100699757B1 (de)
CN (1) CN1196488C (de)
AR (1) AR025512A1 (de)
AT (2) ATE367162T1 (de)
AU (1) AU763970B2 (de)
BR (1) BR0007996A (de)
CA (1) CA2368186C (de)
CY (2) CY1106879T1 (de)
CZ (2) CZ302881B6 (de)
DE (2) DE60035575T2 (de)
DK (2) DK1150678T3 (de)
EE (2) EE05621B1 (de)
ES (2) ES2286995T3 (de)
GB (1) GB0001662D0 (de)
HK (2) HK1041223A1 (de)
HU (1) HU227642B1 (de)
IL (3) IL144730A0 (de)
IS (2) IS2793B (de)
MX (1) MXPA01007821A (de)
MY (1) MY138289A (de)
NO (1) NO330400B1 (de)
NZ (3) NZ525419A (de)
PL (1) PL198098B1 (de)
PT (2) PT1897546E (de)
RU (1) RU2239456C2 (de)
SI (2) SI1897546T1 (de)
SK (2) SK286854B6 (de)
TR (1) TR200102229T2 (de)
TW (1) TWI230067B (de)
WO (1) WO2000045818A1 (de)
ZA (1) ZA200105885B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
MXPA02001694A (es) 1999-08-30 2002-08-06 Aventis Pharma Gmbh Uso de inhibidores del sistema renina-angiotensina en la prevencion de eventos cardiovasculares.
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP1254667A4 (de) * 2000-02-10 2003-03-12 Takeda Chemical Industries Ltd Arzneimittel mit einer kombination von aktiva
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
DE10025308A1 (de) * 2000-05-23 2001-11-29 Bayer Ag Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
PE20020323A1 (es) * 2000-08-22 2002-06-13 Novartis Ag COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
ATE401886T1 (de) * 2000-10-12 2008-08-15 Nissan Chemical Ind Ltd Wirkstoffe zur vorbeugung und behandlung von komplikationen im zusammenhang mit diabetes
WO2002032411A2 (en) * 2000-10-18 2002-04-25 Pfizer Products Inc. Combination of statins and sorbitol dehydrogenase inhibitors
IL155710A0 (en) 2000-11-30 2003-11-23 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
WO2003077912A1 (en) * 2002-03-20 2003-09-25 The University Of Queensland Method of treatment and/or prophylaxis
TW200810743A (en) * 2002-03-22 2008-03-01 Novartis Ag Combination of organic compounds
JP4395633B2 (ja) * 2002-08-29 2010-01-13 学校法人鈴鹿医療科学大学 非神経細胞の神経細胞への分化成熟法、該組成物と該組成物探索法
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
US7772272B2 (en) 2003-04-28 2010-08-10 Daiichi Sankyo Company, Limited Method for enhancing glucose uptake into warm-blooded animal adipocytes
CA2524134C (en) 2003-04-28 2017-07-04 Sankyo Company Limited Adiponectin production enhancer
JP2005232151A (ja) * 2003-04-28 2005-09-02 Iichiro Shimomura 糖取り込み能増強剤
DK1643999T3 (da) * 2003-06-20 2012-01-02 Nephrogenex Inc Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
EP1510208A1 (de) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Metformin-Statin-Kombination enthaltende pharmazeutische Zusammensetzungen
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
WO2005023766A1 (en) * 2003-09-11 2005-03-17 Biocon Limited Salt of atorvastatin with metformin
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
AU2003272084A1 (en) * 2003-10-07 2005-04-21 Biocon Limited SALT OF 1,2,6,7,8,8A-HEXAHYDRO-Beta,Delta,6-TRIHYDROXY-2-METHYL-8-((2S)-2-METHYL-1-OXOBUTOXY)-, (BetaR,Delta R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE
KR100715114B1 (ko) * 2005-02-19 2007-05-10 한국유나이티드제약 주식회사 당뇨병 치료를 위한 약학적 조성물
CN101632673B (zh) * 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途
LT2326632T (lt) * 2008-09-06 2017-09-25 Bionevia Pharmaceuticals, Inc. Naujas epalrestato cholino kokristalas
EP2196476A1 (de) 2008-12-10 2010-06-16 Novartis Ag Antikörperformulierung
WO2013072770A2 (en) 2011-11-15 2013-05-23 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising atorvastatin and glimepiride
WO2015053589A1 (ko) * 2013-10-11 2015-04-16 가톨릭대학교 산학협력단 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물
KR101579656B1 (ko) * 2013-12-12 2015-12-22 가천대학교 산학협력단 프라바스타틴과 발사르탄을 포함하는 약학 조성물
CN110747206B (zh) * 2019-11-05 2021-11-23 昆明理工大学 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9208116D0 (en) * 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
CA2132544C (en) 1992-04-13 2005-10-18 Frank Carey Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
AU1095695A (en) 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
EP0754042A4 (de) * 1994-03-29 2004-06-23 Merck & Co Inc Behandlung von atherosklerose mit imidazolen, die den angiotensin ii-rezeptor blockieren
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ATE220333T1 (de) 1996-04-05 2002-07-15 Takeda Chemical Industries Ltd Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin- sensitivität erhöht
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6262076B1 (en) * 2000-01-28 2001-07-17 Ajinomoto Co., Inc. Pharmaceutical composition for use in the treatment of diabetic neuropathy
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment

Also Published As

Publication number Publication date
SK11102001A3 (sk) 2002-05-09
JP2012051898A (ja) 2012-03-15
IL144730A0 (en) 2002-06-30
CN1338937A (zh) 2002-03-06
CA2368186C (en) 2008-06-03
DK1897546T3 (da) 2011-01-17
ATE485823T1 (de) 2010-11-15
ES2286995T3 (es) 2007-12-16
HUP0105138A3 (en) 2002-11-28
US6894058B1 (en) 2005-05-17
DK1150678T3 (da) 2007-10-08
TWI230067B (en) 2005-04-01
MY138289A (en) 2009-05-29
PT1150678E (pt) 2007-09-14
SI1897546T1 (sl) 2011-02-28
GB0001662D0 (en) 2000-03-15
EP1150678B1 (de) 2007-07-18
EE200100405A (et) 2002-10-15
US20120041010A1 (en) 2012-02-16
ATE367162T1 (de) 2007-08-15
AR025512A1 (es) 2002-12-04
RU2239456C2 (ru) 2004-11-10
CZ302881B6 (cs) 2012-01-04
IL208330A0 (en) 2010-12-30
SK287792B6 (sk) 2011-10-04
IS2793B (is) 2012-08-15
EE201200015A (et) 2012-10-15
CY1110992T1 (el) 2015-06-11
JP2014065718A (ja) 2014-04-17
NO330400B1 (no) 2011-04-04
EP1150678A1 (de) 2001-11-07
TR200102229T2 (tr) 2001-12-21
NO20013812D0 (no) 2001-08-03
US20090186908A1 (en) 2009-07-23
EP1897546A1 (de) 2008-03-12
US20050209128A1 (en) 2005-09-22
NZ536433A (en) 2006-08-31
CZ302893B6 (cs) 2012-01-11
IS2820B (is) 2012-12-15
HK1118209A1 (en) 2009-02-06
SI1150678T1 (sl) 2008-02-29
CN1196488C (zh) 2005-04-13
HK1041223A1 (en) 2002-07-05
WO2000045818A1 (en) 2000-08-10
PL198098B1 (pl) 2008-05-30
HUP0105138A2 (hu) 2002-04-29
IS8978A (is) 2011-08-23
ES2352803T3 (es) 2011-02-23
CY1106879T1 (el) 2012-05-23
CZ20012806A3 (cs) 2002-02-13
SK286854B6 (sk) 2009-06-05
JP2002536332A (ja) 2002-10-29
AU2304700A (en) 2000-08-25
CA2368186A1 (en) 2000-08-10
AU763970B2 (en) 2003-08-07
NZ513061A (en) 2003-06-30
EE05556B1 (et) 2012-08-15
BR0007996A (pt) 2001-10-30
PT1897546E (pt) 2010-12-15
EP1897546B1 (de) 2010-10-27
PL350312A1 (en) 2002-12-02
KR20010089635A (ko) 2001-10-06
IS6016A (is) 2001-07-20
NO20013812L (no) 2001-10-02
ZA200105885B (en) 2002-10-17
DE60035575T2 (de) 2008-04-03
DE60045168D1 (de) 2010-12-09
HU227642B1 (en) 2011-10-28
KR100699757B1 (ko) 2007-03-27
EE05621B1 (et) 2013-02-15
NZ525419A (en) 2004-12-24
IL144730A (en) 2010-12-30
MXPA01007821A (es) 2004-08-19

Similar Documents

Publication Publication Date Title
DE60035575D1 (de) Verwendubg von 3-hydroxy-3-methylglutaryl coenzym a reduktase inhibitoren zur herstellung eines medikaments zur behandlung der diabetischen neuropathie
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
ATE292971T1 (de) (s,s)-reboxetin zur behandlung von peripheren neuropathien
ATE417606T1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
ATE248599T1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE487493T1 (de) Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60100625D1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
EE04356B1 (et) aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis
DE60112431D1 (de) Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
DE69910202D1 (de) EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
DE60318327D1 (de) Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
ATE314850T1 (de) Verwendung einer pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE60128911D1 (de) Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen
DE60001599D1 (de) Verfahren zur Herstellung von cis-1-2-[4-(6-Methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl-pyrrolidin
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE60017174D1 (de) Rivastigmine zur behandlung von augenerkrankungen
DE50012667D1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition